Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 31%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Humana has revised its 2025 earnings per share (EPS) estimate upward to $17.06, reflecting strong second-quarter results and updated guidance, indicating robust financial performance. The company anticipates year-over-year earnings growth for 2027 as margin initiatives are expected to take effect, despite assuming stability in Star ratings. Additionally, Humana's superior Medicare Advantage star rating positions it favorably in a competitive landscape, enhancing its resilience amid potential regulatory changes.

Bears say

The financial outlook for Humana appears negative due to anticipated declines in earnings per share (EPS) for 2026 compared to 2025, primarily influenced by ongoing challenges in Medicare Advantage (MA) and the competitive landscape. Additional risks include increased MA utilization, competition, inadequate reimbursement rates, and a potential decline in both Prescription Drug Plan (PDP) membership and MA Star ratings, which could further hinder growth in healthcare services. Furthermore, management's projections indicate that fiscal year 2027 EPS may fall short by approximately 10% due to necessary investments aimed at improving Star ratings, reflecting a concerning trend in the company’s financial performance.

Humana (HUM) has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 31% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 16 analysts, Humana (HUM) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $298.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $298.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.